The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurogene Inc shares valued at $1,259,623 were purchased by Samsara BioCapital GP, LLC on Nov 26 ’24. At $25.83 per share, Samsara BioCapital GP, LLC acquired 48,770 shares. The insider’s holdings grew to 1,717,127 shares worth approximately $36.97 million following the completion of this transaction.
Also, Cvijic Christine Mikail purchased 24,000 shares, netting a total of over 491,400 in proceeds. Following the buying of shares at $20.48 each, the insider now holds 76,844 shares.
Before that, McMinn Rachel had added 47,500 shares to its account. In a trade valued at $969,000, the Chief Executive Officer bought Neurogene Inc shares for $20.40 each. Upon closing the transaction, the insider’s holdings increased to 47,500 shares, worth approximately $27.94 million.
As published in their initiating research note from BMO Capital Markets on June 27, 2024, Neurogene Inc [NGNE] has been an Outperform and the price target has been revised to $65. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid June. As of April 29, 2024, Leerink Partners has initiated its “an Outperform” rating for NGNE. Earlier on March 21, 2024, William Blair initiated its rating. Their recommendation was “an Outperform” for NGNE stock.
Analyzing NGNE Stock Performance
During the last five days, there has been a surge of approximately 38.81%. Over the course of the year, Neurogene Inc shares have dropped approximately -5.82%. Shares of the company reached a 52-week high of $24.00 on 01/06/25 and a 52-week low of $14.42 on 01/24/25. A 50-day SMA is recorded $20.77, while a 200-day SMA reached $34.74. Nevertheless, trading volume fell to 0.82 million shares from 0.17 million shares the previous day.
Support And Resistance Levels for Neurogene Inc (NGNE)
According to the 24-hour chart, there is a support level at 18.20, which, if violated, would cause prices to drop to 14.88. In the upper region, resistance lies at 24.29. The next price resistance is at 27.06. RSI (Relative Strength Index) is 60.28 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.29, which suggests the price will increase in the coming days. Percent R is at 23.63%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Neurogene Inc (NGNE)?
On January 08, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $45.
